Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Trial of Comparing DA-5222 Single-administration and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects
Sponsor: Dong-A ST Co., Ltd.
Summary
This study is to compare pharmacokinetics and safety profiles of DA-5222 single-administration and co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in healthy adult subjects
Official title: An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Phase 1 Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety After Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2025-06
Completion Date
2025-07
Last Updated
2025-06-06
Healthy Volunteers
Yes
Conditions
Interventions
DA-5222
single dose administration (DA-5222 one tablet once a day)
DA-5222-R1
single dose administration (DA-5222-R1 one tablet once a day)
DA-5222-R2
single dose administration (DA-5222-R2 one tablet once a day)
DA-5222-R3
single dose administration (DA-5222-R3 one tablet once a day)
Locations (1)
Bumin Hospital
Seoul, South Korea, South Korea